Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cevostamab + elranatamab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Cevostamab + elranatamab is an investigational combination therapy being evaluated for relapsed or refractory multiple myeloma. Cevostamab is a bispecific monoclonal antibody that targets FCRH5 (Fc receptor-homolog 5) on malignant plasma cells and CD3 on T cells, mediating T cell–directed cytotoxicity against multiple myeloma cells. Elranatamab is a bispecific antibody that targets BCMA (B cell maturation antigen) on multiple myeloma cells and CD3 on T cells, similarly engaging T cells for targeted cell lysis. This combination is designed to achieve deeper tumor responses by simultaneously targeting two different antigens on myeloma cells and activating endogenous T cell responses[1][4][5].
- Brand names
- Elrexfio
- Other names
- cevostamab + elranatamab
02
Targets
FCRL5 (Fc receptor-like protein 5)BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on cevostamab + elranatamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cevostamab + elranatamab.